Viral infections:
Indications for: XOFLUZA
Treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48hrs and who are otherwise healthy patients ≥5yrs of age, or patients ≥12yrs of age who are at high risk of developing influenza-related complications. Post-exposure prophylaxis of influenza in individuals ≥5yrs of age following contact with an individual who has influenza.
Limitations of Use:
Consider available information on drug susceptibility patterns for circulating influenza strains when deciding whether to use.
Adults and Children:
<5yrs (treatment or post-exposure prophylaxis); <12yrs (treatment of high risk of developing influenza-related complications): not established. ≥5yrs: (20–<80kg): 40mg as a single dose; (≥80kg): 80mg as a single dose.
XOFLUZA Warnings/Precautions:
Increased risk of treatment-emergent resistance in patients <5yrs of age. Potential secondary bacterial infections; treat appropriately. Pregnancy. Nursing mothers.
XOFLUZA Classification:
Polymerase acidic (PA) endonuclease inhibitor.
XOFLUZA Interactions:
Avoid coadministration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, or zinc). May reduce efficacy of live attenuated influenza vaccines.
Adverse Reactions:
Diarrhea, bronchitis, nausea, sinusitis, headache, vomiting; hypersensitivity reactions.
Generic Drug Availability:
NO
How Supplied:
Tabs—1
